Sentences with phrase «cell acute lymphoblastic leukemia»

But excessive Notch signaling causes thymocyte transformation and T cell acute lymphoblastic leukemia (T - ALL).

Abnormally expressed in cancer cells, the protein was found to promote the proliferation of B cells in B - cell acute lymphoblastic leukemia

B - cell acute lymphoblastic leukemia (B - ALL) is an aggressive cancer that originates from a type of white blood cell called the B lymphocyte.

In a patient with relapsed B - cell acute lymphoblastic leukemia, a single dose of 5 × 10 (4) / kg 1928zT2 T cells resulted in robust expansion and leukemia eradication and led to complete remission.

Take recent research into T cell acute lymphoblastic leukemia, an aggressive blood cancer.

Researchers at Penn State College of Medicine, working with Chinese and American colleagues, have discovered a novel way to enhance and restore cancer suppressor activity in B - cell acute lymphoblastic leukemia, resulting in better outcomes in a pre-clinical model of the disease.

In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.10

High - throughput cell transplantation establishes that tumor - initiating cells are abundant in zebrafish T - cell acute lymphoblastic leukemia.

Deletion of genes encoding PU.1 and Spi - B in B cells impairs differentiation and induces pre-B cell acute lymphoblastic leukemia

Whole genome and whole transcriptome sequencing of 31 pediatric Asian patients with T - cell acute lymphoblastic leukemia found that about 10 percent had the same alteration in a non-coding region of DNA.

Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the drugs that received the FDA's stamp of approval in 2017.

It's the most common cancer - causing gene in T - cell acute lymphoblastic leukemia.

The FDA granted approval to a new, first - in - class immunotherapy — tisagenlecleucel (Kymriah, Novartis)-- for the treatment patients up to 25 years old with B cell acute lymphoblastic leukemia (B - ALL) that is refractory or has relapsed after at least two previous treatments.

The FDA approves Blincyto (blinatumomab) for use in the treatment of B cell acute lymphoblastic leukemia (ALL).

The new study, published March 14 in the Journal of Clinical Investigation, focused on a particularly aggressive form of B - cell acute lymphoblastic leukemia (B - ALL), the most prevalent type of leukemia in children and young adults.

«Role of RNA binding protein in driving cancer, leukemia study reveals: Abnormally expressed in cancer cells, the protein was found to promote the proliferation of B cells in B - cell acute lymphoblastic leukemia.»

The therapy has led to remission rates as high as 90 % in children and young adults with B - cell acute lymphoblastic leukemia (ALL); however, the side - effects can be extreme and difficult to manage.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

Novartis» experimental product, CTL019, is being recommended for children and young adults aged 3 to 25 who have hard - to - treat (or recurring) forms of the rare blood cancer B - cell acute lymphoblastic leukemia (ALL).

We demonstrate IM - Fusion on two separate transposon screens of 123 mammary tumors and 20 B - cell acute lymphoblastic leukemias, respectively.

Not exact matches

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

«Protein isolated from baker's yeast shows potential against leukemia cells: Researchers performed in vitro trials to test the effect of L - asparaginase on acute lymphoblastic leukemia cells and published the results in Scientific Reports.»

In PLAT - 02, the CAR T cells are reprogrammed to recognize and target the CD19 protein that is expressed by most precursor B acute lymphoblastic leukemia cells.

The current research involved acute lymphoblastic leukemia (ALL) cells, a common type of childhood cancer.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment of Philadelphia chromosome - negative relapsed or refractory B - cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.

Effects of the chemokine stromal cell - derived factor - 1 on the migration and localization of precursor - B acute lymphoblastic leukemia cells within bone marrow stromal layers.

CAR T - cell treatment, on the other hand, is being widely tested in children and has shown impressive effectiveness against the most common childhood leukemia, called acute lymphoblastic leukemia.

Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.

Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B - cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with relapsed or refractory DLBCL.

A phase I / II trial of KTE - C19 (anti-CD19 CAR T cells) for pediatric and adolescent subjects with relapsed / refractory B - precursor acute lymphoblastic leukemia -LRB-

We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) / atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B - lineage acute lymphoblastic leukemia (ALL), T - cell ALL, and chronic lymphocytic leukemia (CLL).

CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response.

ONC201 demonstrated (GI50 1 - 8 µM) dose - and time - dependent efficacy in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), diffuse large B - cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T - cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines including cells resistant to standard of care (dexamethasone in MM) and primary samples.

Phosphoinositide - dependent and - independent natural cell killing of pre-B acute lymphoblastic leukemia cells by IL - 2 activated NK cells and NK - 92ci Clin Exp Immunol.

In addition, we have access to new agent trials through the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) consortium, and we offer CAR T - cell therapy for eligible children with relapsed or refractory acute lymphoblastic leukemiLeukemia and Lymphoma (TACL) consortium, and we offer CAR T - cell therapy for eligible children with relapsed or refractory acute lymphoblastic leukemialeukemia (ALL).

In 2006, Shelia Gannon was close to the end of a losing battle against acute lymphoblastic leukemia (ALL), a form of cancer that causes abnormal blood formation and a shortage of red and normal white blood cells and platelets.

A group of researchers at the Baylor College of Medicine has published the results of a study in the journal PLoS ONE demonstrating that a concentrated form of the compound sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the number of acute lymphoblastic leukemia cells in a lab setting.

Lead study author Dr. Daniel Lacorazza noted that «acute lymphoblastic leukemia is a type of cancer of the white blood cells common in children... there is about an 80 percent cure rate, but some children don't respond to treatment.